The new semaglutide gene study links rare gene changes to much less weight loss on semaglutide. These changes occurred in about 1 in 400 treated adults. It's a possible explanation for a few disappointing responses. The finding doesn't show who needs a genetic test or a different medicine.

What the semaglutide gene study found

As of November 12, 2026, the day this article was written, a Nature Metabolism paper published November 11 offers a new genetic clue.

GLP1R is the gene—the body's instruction—for the GLP-1 receptor, a cell switch semaglutide activates. GLP-1 is a gut hormone involved in appetite and blood sugar. A gene variant is a change in that instruction.

The Helix Research Network held genetic and health records for 351,818 people. The treatment analysis involved 13,725 adults taking semaglutide or tirzepatide. Of those, 33 had GLP1R changes expected to weaken the switch. Researchers compared them with people matched on medicine, dose and key health characteristics.

They measured weight change using the lowest recorded weight between six and 12 months after treatment began.

Medicine People carrying the changes Average weight loss in carriers Average loss in matched people without the changes
Semaglutide 17 2.4% 8.8%
Tirzepatide 19 13.3% 15.2%

These are percentages of starting body weight, not percentages of people who responded. The comparisons were within each medicine, rather than against a placebo, a treatment without active medicine. Some people contributed separate treatment periods for both drugs, so the rows overlap.

The large network made it possible to find rare carriers. The groups for each medicine were still very small. That difference matters when deciding how much a headline can tell one person taking semaglutide.

What this means for a slow response

These particular changes affected a small share of treated people. The finding leaves the everyday questions about treatment just as relevant.

A 2024 clinical-practice study in JAMA Network Open found that weight reduction was associated with dose and continued medication use. The condition being treated mattered too. Those details matter when a clinician looks at someone's weight changes.

A useful review puts dose changes, treatment gaps, side effects and other medicines on a timeline. Someone early in treatment has a different question from someone who has had little change over many months. The prescriber sets the actual dose and any adjustment.

Losing weight and then maintaining it is also different from having little response from the start. The tirzepatide plateau guide explains that pattern in the related medicine. A flat stretch on the scale doesn't identify a gene variant.

Why tirzepatide appeared less affected

Tirzepatide also activates the GIP receptor, a second cell switch responding to another gut hormone. The network's November 11 announcement describes these two targets.

The paper's authors propose that the second pathway may partly make up for weaker GLP-1 signaling. They say direct experiments are needed to establish that explanation.

The study was observational: researchers examined existing treatment rather than assigning medicines by chance. A less affected group average does not prove every carrier responds normally to tirzepatide.

The wider tirzepatide-versus-semaglutide comparison covers the other evidence behind choosing between them. This finding adds a question to that discussion. It doesn't establish a rule to switch medicines whenever semaglutide has disappointed.

What it does not mean for genetic testing

Finding a link between a gene and weight change is different from showing that testing improves care. This study didn't compare treatment chosen using genetic results with usual care.

A useful test needs more than an interesting association. Its results must be reliable, and there needs to be evidence about what happens when clinicians act on them. An uncertain result can add another question without resolving the original one.

Some changes in this study were classified by computer predictions. Most carriers had genetic backgrounds similar to European populations. Larger studies across more backgrounds would help clarify how widely the findings apply.

The paper suggests a future role for matching treatment to genes. It doesn't establish routine testing for everyone whose weight loss is slower than expected.

For someone with a disappointing response, the broader options after an inadequate GLP-1 response still need their own clinical assessment. A genetic explanation is one possibility, not a complete account of the person's treatment history.

What changes for a compounded prescription

The percentages above do not establish the expected results of a compounded prescription. Compounded means a pharmacy prepares a medication for a prescription.

Semaglutide and tirzepatide prescribed through Promise are dispensed by a licensed U.S. compounding pharmacy as compounded medications. These are different from an FDA-approved product: the formulations offered here are not FDA-approved.

As of November 12, 2026, the day this article was written, FDA explains that it does not verify compounded drugs' safety, effectiveness or quality before marketing.

A licensed provider may still prescribe — that decision is between you and your doctor.

The genetic finding doesn't settle which preparation suits a person. That discussion still involves the actual prescription, the response so far and the person's health needs.

What to watch next

The next useful question is whether choosing treatment using genetic results actually improves outcomes. That would require studying a testing strategy, rather than only looking back at existing care.

For someone already taking semaglutide, a follow-up can begin with the treatment record: what was prescribed, when it changed and what happened afterward. A new explanation for rare responses deserves attention without replacing that review.

At Promise, a licensed provider reviews every request, and not everyone qualifies.